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Francesco Facciolo, MDǁIN THE FIELD of thoracic surgery, one of the key problemsin lung resection is the management and function of the
residual lung, which has the potential to interfere with both the
pulmonary and cardiovascular systems, and, therefore, inﬂu-
ence surgical outcome in terms of morbidity and mortality.
Between 2007 and 2013, 5 papers addressing preoperative
evaluation and risk stratiﬁcation were published.1-5 However,
the members of the task forces responsible for these documents
did not include all the professionals involved in the preoper-
ative surgical evaluation, and the documents mainly addressed
the stratiﬁcation of respiratory risk. In 2014, new guidelines6,7
addressing cardiac risk assessment in the perioperative period
were published and proposed new and distinct approaches,
rendering the literature on the assessment and risk stratiﬁcation
of thoracic surgery patients even more confusing. Guidelines
are important because they have the potential to improve
outcomes and quality of care, especially in high-risk surgical
patients (HRSPs), and also improve the management of health-
care resources.
The most appropriate person to serve as the “perioperati-
vist”—overseeing the involvement of all other stakeholders in
the preoperative, intraoperative, and postoperative phases of the
care of thoracic patients—is the anesthesiologist because of the
nature of this professional’s training and practice, which
already require the assessment, evaluation, and preparation of
patients with a multitude of complex comorbidities for
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530 Journal of CardiothoAround the world, the role of the anesthesiologist is being
expanded thanks to the introduction of innovative delivery care
models, such as enhanced recovery after surgery9 and the
perioperative surgical home,10,11 which are aimed at improving
patient outcome while increasing efﬁciency. Indeed, the 2014
ACC/AHA Guideline on Perioperative Cardiovascular Evalua-
tion and Management of Patients Undergoing Noncardiac
Surgery recognized the anesthesiologist as the ideal “perioper-
ative physician” to coordinate the preoperative evaluation due
to the anesthesiologists’ unique and intensive training on the
speciﬁc demands of the proposed surgical procedures.8
In this article, the authors discuss the key items relevant to
preoperative evaluation, paying particular attention to the multi-
disciplinary approach, as depicted in Figure 1. The authors’ goal
was to establish a simple algorithm that is easy to apply in the
clinical setting, an algorithm that takes into consideration the
assessments made by the pulmonologist, medical and radiation
oncologists, cardiologist, anesthesiologist, and, of course, the
thoracic surgeon. The authors reviewed other recently published
algorithms and considered the similarities and differences
between them to identify the key steps that a preoperative
functional evaluation should contain.
THE PULMUNOLOGIST’S PERSPECTIVE
In most cases, it is the pulmonologist who makes the
diagnosis of lung cancer, and the patient then is referred to a
surgeon. The evaluation of lung function status is one of the
most important steps in estimating the risk of postoperative
respiratory failure and outcome. Functional status is a reliable
predictor of perioperative and long-term cardiac events, and
patients with preoperative reduced functional status have a
higher risk of developing complications,12,13 whereas those
with a good preoperative functional status are at lower risk. The
majority of reports base the preoperative evaluation of respi-
ratory function on spirometry parameters—in particular, forced
expiratory volume in the ﬁrst second (FEV1) and carbon
monoxide diffusing capacity (DLCO). These parameters are
evaluated together and assessed as percentages of predicted
values (pp), thereby taking into consideration differences
related to patient age, height, weight, and sex. However,
spirometry requires patient cooperation and its results must
be interpreted cautiously before validation.14-16 There is a
general consensus that further tests are unnecessary when FEV1
and DLCO are normal (ie,480% of predicted values) and
the patients are evaluated as low risk. For ppFEV1 andracic and Vascular Anesthesia, Vol 30, No 2 (April), 2016: pp 530–538
Fig 1. The “true” multidisciplinary approach requires a physician
team leader, and anesthesiologists are uniquely positioned to serve
as “perioperativists,” actively involving all others healthcare
participants.
LUNG RESECTION SURGERY 531ppDLCO440% buto80%, the surgical risk is considered as
intermediate, but this result should be subjected to interpreta-
tion, taking into account the patient’s cardiovascular reserve
(see the sections describing the anesthesiologist’s and the
cardiologist’s perspective).
Some authors recently have extended this range to less than
40%, considering values as low as 30% as presenting an
intermediate risk;3,4,17-19 although the patient populations
evaluated in such studies with very low levels of lung function
were heterogeneous and the results were not compared with
patient outcomes.17,18 Nevertheless, this cut-off has been
introduced into clinical practice on the basis of indirect
evidence and expert consensus opinion.4
In a recent report on video-assisted thoracoscopic surgical
(VATS) lobectomy, a preoperative FEV1 or DLCOo30% of
predicted values was shown to be a contraindication for
surgery, and no other tests for the risk stratiﬁcation of lung
function were recommended at this point.20 On the other hand,
a number of other studies have suggested leaving the limit at
40%.5,21,22 In summary, the scientiﬁc data published to date are
inconsistent, making it difﬁcult to formulate an ofﬁcial guide-
line. Because the lower proposed thresholds can be applied
safely, with strong support from the literature, it seems
reasonable to maintain a “safety margin” by considering the
40% cut-off and evaluating patients with values between 30%
and 40% in more depth before pulmonary resection.
Arterial blood gas analysis should be performed in all
patients scheduled for an elective pulmonary resection as part
of the basic pulmonary function tests.22 There is no consensus
regarding a value of arterial oxygen tension that clearly
indicates an increased risk for pulmonary resection. A
PaCO2445 mmHg has been associated with an increased risk
of postoperative complications, but it is not considered to
preclude pulmonary resection.23 The presence of 1 of the 3
following conditions generally is associated with an increased
risk of postoperative complication and/or respiratory failure:
FEV1o30% of the predicted value, PaO2o60 mmHg, or
PaCO2450 mmHg.
24,25 The cardiopulmonary exercise test
(CPET) commonly is used to provide information about the
real cardiorespiratory reserve, and it can be performed bymeans of either a “high-technology” test (ie, measurement of
peak oxygen consumption [VO2 max]) or a “low-technology”
test (eg, the shuttle test, stair climbing, or the 6-minute walk
test with or without the measurement of oxygen saturation).3-5
The various published guidelines recommend different tests;
for example, one recommends the shuttle test over the stair
climbing test,5 and another suggests a VO2 cut-off of 10 mL/
kg/min,4 rather than the standard value of 15 mL/kg/min.26
CPET generally is recommended in all patients with
abnormal lung function (ie, in patients with FEV1 and
DLCOo80%). On the basis of indirect evidence and the
consensus opinion of experts, but not objective clinical
evidence, the DLCO cut-off value recently was changed from
80% to 60%.4 Some guidelines suggest that exercise tests
should be performed in all patients with FEV1 and
DLCOo80% as the ﬁrst step in risk stratiﬁcation, whereas
other authors recommend that split-lung function tests are
performed ﬁrst and then only followed by CPET in patients
with ppDLCO and/or ppFEV1o30%.3,5
Many different opinions have been published over recent
years, generating an ambiguous situation that does not help
clinicians resolve their doubts or advise them about the most
suitable choices.1-5 For concrete conclusions to be drawn,
conclusive data are required, generated from large studies that
compare parameters to outcome, type of surgery, and preoper-
ative patient selection and that summarize all the different
practitioner points of view.
A clear and simple guideline for clinicians is needed. The
authors’ response to this need is the following: high-technology
testing in patients with ppDLCO and/or ppFEV1o40%
followed by the stratiﬁcation of patients with values ranging
from 40% to 80% with “low-technology” tests (eg, stair
climbing or the 6-minute walk test). If performance in these
tests is less thano22 m oro400 m, respectively, these
patients should be evaluated using a “high-technology” test
(measurement peak oxygen consumption [VO2 max]).THE ANESTHESIOLOGIST’S PERSPECTIVE
Over the past decades, anesthesiologists have expanded
their focus outside the operating room. This development is not
unique to the United States; many countries in Europe have
developed strategies to increase the role of the anesthesiologist
in the perioperative setting.8,9,27,28 None of the most recent
studies on preoperative evaluation in thoracic surgery has taken
into consideration the role of the anesthesiologist or the
intensivist1-5; thus, these studies have not embraced the real
advantages that a truly multidisciplinary team can offer.
According to the 2014 ESC/ESA guidelines on noncardiac
surgery, the anesthesiologist, who is expert on the speciﬁc
domain of the proposed surgical procedure, usually should
coordinate the preoperative evaluation.7
The aim of the anesthesiologist is to improve the surgical
outcome by identifying potential anesthetic difﬁculties and any
existing medical conditions and improving safety by assessing
and quantifying risk, thereby allowing perioperative care to be
planned. In this way, cardiac risk assessment plays an
important role. Although the American Society of Anesthesi-
ologists’ classiﬁcation of “physical status” for describing
DELLA ROCCA ET AL532common clinical problems is used widely, multiple variations
have been observed among the assessments of individual
anesthesiologists.29 The revised cardiac risk index (RCRI)
should be taken into account to estimate cardiovascular risk,
with its intrinsic limitations (see the section on the cardiolo-
gist’s prospective) as either “moderately good or moderately
bad.”30
In thoracic surgery, a new scoring system known as
thoracic-RCRI (ThRCRI) recently was introduced by Brunelli
et al.31 The ThRCRI is calculated according to the following
system: pneumonectomy 1.5 points, previous ischemic heart
disease 1.5 points, previous stroke or transient ischemic attacks
1.5 points, creatinine42 mg/dL 1 point. It stratiﬁes patients
into the following 4 risk categories: group A, low risk, 0 points;
group B, intermediate risk,Z1.5 points; groups C and D, high
risk, Z2 points.32 A ThRCRI score of at least 2 points, any
cardiac condition requiring medication, newly suspected car-
diac condition, or an inability to climb 2 ﬂights of stairs should
prompt cardiology consultation.4,32 Surprisingly, only a few
studies have evaluated this scoring system; moreover, its
clinical application in daily clinical practice was found to be
poor. One recent article found that the scoring system failed to
predict the risk of cardiac complications accurately.30
However, in accordance with the ESC/ESA guidelines, the
assessment of functional capacity status by means of daily
living activities in terms of metabolic equivalents (METS) are
used widely by anesthesiologists and cardiologists, and only
patients with METSr4 are referred to the cardiologist for
consultation.6,7 Nevertheless, several studies recently examined
the hypothesis that preoperative natriuretic peptides could help
identify patients at risk of adverse cardiac events after major
noncardiac surgery.34,35 However, the power of these tests with
their high negative predictive value (NPV) is particularly
helpful in “opposite-direction” patients with low levels of
natriuretic peptides (o100 pg/dL) who exhibit fewer compli-
cations.36 These tests should be reserved for patients with
METSo4.7
A preoperative cardiology consultation is only necessary for
patients with METSr4 and clinical risk factors.7,8 When the
outcome of the cardiac examination is positive (assessed using
clinical evaluation and noninvasive tests), the patient needs to
be assessed using the CPET, which provides information about
the real cardiopulmonary reserve by evaluating VO2 max
(Fig 2). A patient who attains and exceeds a VO2 max420
mL/kg/min is considered to be low risk; a patient with a VO2
max between 15 to 20 mL/kg/min is considered to be
intermediate risk; and a patient with a VO2 maxo15 mL/kg/
min is considered to be high risk. When the results of the
cardiac examination are negative (assessed using clinical
evaluation and noninvasive tests), the patient’s case is moved
to the right side of the ﬂowchart (Fig 2). If the values of
ppFEV1 and ppDLCO are less than 40%, the patient’s case is
returned to the left side of the ﬂowchart and the patient is
required to undergo the CPET. If the value of VO2 max is420
mL/kg/min, between 15 to 20 mL/kg/min, oro15 mL/kg/min,
the patient is classiﬁed as low, medium, or high risk,
respectively. If a patient with negative cardiac examination
results and METS44 exhibits a ppFEV1 and ppDLCO
between 40% to 80%, it then becomes advisable to measurethe real cardiorespiratory reserve using “low-technology” tests
(eg, the stair climbing test and the 6-minute walk test in the
presence or absence of exercise-induced oxygen desaturation
measurements). A patient who achieves the cut-off of422 m
for the stair climbing test or4400 m for the 6-minute walk test
is considered to have passed the test and, as such, is classiﬁed
as low risk. On the other hand, if a patient does not achieve
these cut-offs, then further assessment using the VO2 max is
performed; VO2 max values420 mL/kg/min, between 15 to
20 mL/kg/min, oro15 mL/kg/min are considered low,
medium, or high risk, respectively. If the outcome of a cardiac
examination is negative with METS44 and ppFEV1 and
ppDLCO480%, the patient is classiﬁed as low risk.
Postoperative recovery in the intensive care unit (ICU)
should be planned before surgery for all patients requiring
postoperative organ support (eg, cardiac, respiratory, renal
support) and for lung transplantation patients. In some cases,
the individual risk of mortality is45% and the patients are
described as HRSP due to the type of surgery.37 A patient with
an assigned risk score of more than 2 standard deviations
greater than the mean value for the entire population under-
going this kind of surgery37 is considered to be an HRSP. ICU
admittance requires postoperative care “tailored” with consid-
eration of the patient’s reserve as a “pro-active” approach in
terms of hemodynamic optimization38,39 (ie, values of arterial
pressure, heart rate, cardiac index, oxygen delivery, lactate
levels, and central venous saturation should be maintained
within acceptable ranges). In selected patients, respiratory
optimization also could be “tailored”,40,41 although others have
disputed this proposal.42 This would entail improving post-
extubation oxygenation with continuous positive airway pres-
sure or noninvasive ventilation. As described by Boyd and
Jackson,37 this approach rarely is applied due to a lack of
knowledge about the patient’s baseline risk, a general lack of
understanding about this type of analysis, and limited ICU
resources. This concept reinforces the need for an “effective-
ness” approach to high-risk patients in thoracic surgery. Thus,
HRSPs should be scheduled for ICU admittance as part of the
preoperative plan. If, for any reason, a bed in the ICU is not
available, the planned surgery should not proceed.28 If intra-
operative complications occur, it goes without saying that
recovery in the ICU constitutes a “reactive” response to the
problem. In support of the authors’ hypothesis outlined here, a
recent multicenter 5-year observational study conducted in 80
general ICUs reported that the most frequent cancer types
admitted to the ICU after elective surgery were colorectal
carcinoma and lung carcinoma; both pathologic conditions
were associated with a short length of stay and low mortality.43THE CARDIOLOGIST’S PERSPECTIVE
In relation to the incidence of perioperative major adverse
cardiac events (MACE) (ie, deaths and myocardial infarction
within 30 days of surgical intervention), intrathoracic (non-
major) surgery was considered to present an intermediate level
of risk (1%-5%), whereas pneumonectomy and lung transplant
surgery were considered to present high risk (45%) by the
2014 ESC/ESA guideline for patients undergoing noncardiac
surgery.6 On the other hand, in the 2014 ACC/AHA Guideline
Fig 2. Algorithm ﬂowchart for the evaluation of cardiopulmonary reserve before lung resection in lung cancer patients. Forced expiratory
volume in the ﬁrst second (FEV1) and carbon monoxide diffusing capacity (DLCO) evaluated together and assessed not as absolute values but as
postoperative percentages of predicted values (pp). Abbreviations: CV, cardiovascular; BNP, brain natriuretic peptide; CPET, cardiopulmonary
exercise test; VO2 max, peak oxygen consumption; SCT-6MWT, stair climbing test and 6-minute walk test.
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of Patients Undergoing Noncardiac Surgery, only 2 levels of
risk are considered: “low-risk” procedures, in which the
combined surgical and patient characteristics predict a risk of
MACE o1% (eg, cataract and plastic surgery procedures), and
“elevated-risk” procedures, which include all other major
procedures with a risk of MACEZ1%.7
However, it also is important to note that morbidity and
mortality related to the untreated underlying conditions may
change the surgical outcome. Consequently, the cardiology
evaluation may inﬂuence the perioperative course by attempt-
ing to reduce the cardiac risk without inﬂuencing the decision
to perform the intervention. It is standard practice today to refer
cardiac patients with active cardiac conditions (unstable coro-
nary syndrome, decompesated heart failure [NYHA functional
class IV; worsening or new-onset heart failure], signiﬁcant
arrhythmias, severe valvular disease) for cardiology evaluation;
on the other hand, cardiac patients who do not present with
active symptoms are stratiﬁed poorly because of the apparent
reduction of indication for a cardiology visit.
Both the ESC/ESA and ACC/AHA guidelines recommend
the RCRI as the preferred scoring tool to assess cardiac risk in
patients undergoing noncardiac surgical procedures.6,7 Six
independent predictors of complications were identiﬁed and
included in the RCRI: high-risk type of surgery, history of
ischemic heart disease, history of congestive heart failure,
history of cerebrovascular disease, preoperative treatment with
insulin, and preoperative serum creatinine42.0 mg/dL. The
index classiﬁes patients into 5 different groups and assigns risk
as follows: group 0 = low risk; groups 1 and 2 = intermediaterisk; and groups 3, 4, and 5 = high risk.44 However, the ability
of the RCRI to estimate the risk of cardiac complications after
surgery has been reported as limited; for example, its capacity
to discriminate between patients who were at low versus high
risk for perioperative cardiac complications after mixed non-
cardiac surgery was considered moderate.30 Moreover, the
RCRI was unable to discriminate between low- and high-risk
patients undergoing vascular noncardiac surgery who generally
exhibited increased perioperative cardiac risk,45-47 and other
results available in the literature do not support its use for
predicting all-cause mortality after major noncardiac surgery.30
The thoracic surgery algorithms proposed by Brunelli et al4
and Licker et al48 focus on the evaluations provided by the
cardiologist in terms of the ThRCRI or RCRI score, but the
ESC/ESA6 recommends that if patients scheduled for thoracic
surgery present in good physical status, then they should
proceed to surgery without the need for a cardiologist’s
evaluation. It has been considered unethical and unnecessary
to waste resources on these patients in the absence of any
speciﬁc evidence.33 In the authors’ opinion, in cases of poor or
moderate functional vital capacity, the anesthesiologist should
refer patients to a cardiologist as soon as possible for the
optimization of their medical therapy (eg, statins, beta-block-
ers). Two weeks before surgery usually is an adequate time
interval to establish the beneﬁts of the new pharmacologic
treatment. Noninvasive testing only should be considered for
selected cases, such as in patients with coronary artery
revascularization.
In patients at increased risk of postoperative morbidity,
noninvasive stress testing is expensive and has been shown to
DELLA ROCCA ET AL534have a low predictive positive value (ie, it has a high false
positive rate), which might cause more harm than good.49,50
Functional capacity often is expressed in terms of METS, in
which 1 MET is the basal oxygen consumption of a 40-year-
old man weighing 70 kg. In the literature addressing perioper-
ative management, functional capacity is classiﬁed as excellent
(410 METS), good (7-10 METS), moderate (4-6 METS), poor
(o4 METS), or unknown. Perioperative cardiac and long-term
risks are increased in patients unable to perform 4 METS of
work during daily activities. Guidelines only recommend a
preoperative consultation with a cardiologist for patients with
METSr4 and clinical risk factors.51,52
For the ﬁrst time, the 2014 ESC/ESA guidelines clearly
mentions use of the biomarker brain natriuretic peptide (BNP).6
The measurement of plasma levels of BNP or its N-terminal
fragment is being used increasingly in the perioperative
setting.53,54 A number of studies recently examined the
hypothesis that elevated preoperative plasma concentrations
of natriuretic peptides can be used to identify patients at risk for
adverse cardiac events.55,56 However, considering the data
published to date, the assessment of serum biomarkers for
patients undergoing noncardiac surgery cannot be proposed for
routine use, although it may be considered in high-risk patients
(METSr4 or with a RCRI41 for vascular surgery and42
for nonvascular surgery).
Supraventricular arrhythmias and, in particular, atrial ﬁbril-
lation (AF) are important complications in thoracic surgery,
occurring in up to 44% of patients after pulmonary and
esophageal surgery.40 The incidence of AF is associated with
an increased risk of pulmonary complications, increased length
of hospital stay, and increased mortality. The 2014 AHA
guidelines for the management of patients with AF suggest
treating patients who develop AF after cardiac and thoracic
surgery with a beta-blocker unless contraindicated; the guide-
lines also mention the preoperative administration of amiodar-
one in patients at high risk of developing AF while undergoing
cardiac and thoracic surgery.57Fig 3. The combination of functional capacity, patient risk, and
type of surgery and the need for patient tailoring. Abbreviation: VO2
max, peak oxygen consumption.SURGICAL PERSPECTIVE
In the early stage of non–small cell lung cancer, surgery
continues to present the best option.58-61 However, due to
increases in life expectancy; pollution; and cigarette use, abuse,
and misuse, lung resection also often is required in patients
with decreased pulmonary function and increased cardiovas-
cular risk—in other words, in HRSPs.37 The extent of lobar
resection (ie, lobectomy, bilobectomy, sleeve-lobectomy up to
pneumonectomy, and sublobar resections [ie, segmentectomy
and wedge resection]) depends on oncologic staging and the
clinical impact on the patient’s functional status.59,60 Media-
stinal lymph node dissection is essential to achieve accurate
staging, and together with lung resection improves the survival
rate. The use of video-assisted and robotic-assisted thoracic
surgery (VATS and RATS) are becoming increasingly popular,
such that they constitute 2 of the most common forms of
surgery practiced in many institutions today.61-64 These
approaches often are associated with quicker recovery times,
shorter lengths of hospital stay, and lower complication
rates.65,66 When feasible, from both the technical and oncologicperspectives, VATS (and often RATS) provides an optimal
strategy for patients with marginal function and early stage I or
II lung cancer and for patients with pulmonary metastatic
lesions (Fig 3).5,20,58-61 The level of cardiac risk that a patient
presents also can guide the type of surgery selected and may
favor less invasive interventions, such as VATS and RATS,
that generally are correlated with lower rates of overall
perioperative morbidity in terms of pneumonia and atrial
arrhythmia.64-66 Thanks to these advances in surgical care,
morbidity and mortality rates after lung resection have
decreased signiﬁcantly over time. The current rates of mortal-
ity, as reported by the Society of Thoracic Surgeons and the
European Association of Cardio-Thoracic Surgery, are between
1.6% to 2.3% after lobectomy and 3.7% to 6.7% after
pneumonectomy.4,67,68 Indeed, a growing body of evidence
demonstrates improved surgical outcomes and better long-term
survival rates in patients treated by surgeons specializing in
lung cancer in high-volume cancer centers.69,70 Another
important medical advancement has come in the form of
stereotactic ablative radiotherapy (SABR). SABR can be
chosen as an alternative to surgery, especially in high-risk
patients, for the treatment of early stage non–small cell lung
cancer. Clear beneﬁts of SABR have been reported; however,
although overall survival rates at 1 year were comparable
between SABR and sublobar resection (81%-85.7% v 92%,
respectively), overall 3-year survival was signiﬁcantly higher
after sublobar resection (87.1% v 45.1%-57.1%).71
A ﬁnal, yet very important, consideration is that the surgeon
must take into account the views of the patient and their
caregivers and their willingness to accept, or not, the degree of
disability that may be endured over the course of the post-
operative period. As eloquently discussed in a narrative article
about quality of life, the patient’s wishes always should be
respected.72
OTHER RISK FACTORS
The presence of multiple risk factors in thoracic surgery
could change preoperative risk stratiﬁcation and perioperative
management. Comorbidities other than cardiac disorders in the
lung resection surgical population could lead to increases in
LUNG RESECTION SURGERY 535morbidity and mortality and may require more detailed
explanation compared with those occurring in other patient
populations.
Renal Disease
Preoperative kidney disease is an independent risk factor for
adverse postoperative cardiovascular outcomes, including myo-
cardial infarction, stroke, and the progression of heart fail-
ure.6,36 Preoperative end-stage renal disease and hemodialysis
increase the mortality rate after pulmonary resection by
approximately 4-fold.73-75 In the Society of Thoracic Surgeons
(STS) database, postoperative renal dysfunction after pulmo-
nary resections, deﬁned as the doubling of plasma creatinine
levels or the requirement for renal replacement therapy, was
reported to occur in 1.4% of surgery patients and has been
identiﬁed as a strong predictor of mortality and composite
major morbidity.75-77 However, the true incidence of acute
kidney injury in lung surgery likely is underestimated due to
the use of different deﬁnition criteria and the absence of any
systematic measurement of creatinine levels.78,79
Obesity
The impairment of central responses and sleep-disordered
breathing associated with obesity can lead to hypercapnia and
hypoxia.80 However, in lung surgery, a high body mass index
is not associated with an increased risk of mortality.80 In all
patients, the use of aggressive pain control, early mobilization,
pulmonary hygiene, physical therapy, and VATS procedures
contribute to maintaining low morbidity rates.81 Nevertheless,
respiratory complications after standard pneumonectomy for
lung cancer are 5-fold more frequent in overweight and obese
patients than in subjects with a body mass indexo25 kg/m2.82
Age
Age has been identiﬁed as an independent predictor of
complications arising from lung resection,5,83,84 the severity of
which depends on the grade of surgery. The British Thoracic
Society has shown that pneumonectomy is associated with higher
mortality risks in the elderly and that age should be a factor in
deciding suitability for pneumonectomy.85,86 However, with
careful preoperative selection, patients older than 70 years under-
going wedge resection, segmentectomy, or lobectomy with good
exercise tolerance and adequate cardiopulmonary reserves have
not shown higher morbidity and mortality risk.86 For example, 1
study assessing complications and outcomes after pulmonary
resection in patients ages 80 to 89 reported no postoperative
deaths in 40 patients undergoing lesser resection (16 lobectomies
[40%], 12 segmentectomies [30%], and 12 wedge resections
[30%]).87 Nevertheless, surgical risk depends on comorbidities,
the probability of which generally increases with age.
DISCUSSION
In the preoperative evaluation of patients undergoing lung
resection, all professionals (surgeon, pulmonologist/oncologist,
radiologist, and anesthesiologist) normally should meet 1 day a
week to discuss the most complex cases, their timing, and their
course as part of a hospital-approved protocol. The need for a
multidisciplinary approach that encompasses the differentaspects of preoperative patient evaluation should be addressed
and discussed by pulmonologists/oncologists, cardiologists,
surgeons, and anesthesiologists. After a decision about the
patient’s management is reached, a report should be sent to the
practitioners who attended the meetings. On the other hand,
routine cases should be managed as a regular preoperative
workup, including the traditional testing, as previously
described. Simpliﬁcation of the available algorithms reported
in the literature should lead to easier clinical application.1-5,48
As in all management situations, a single practitioner should
be responsible for coordinating the preoperative evaluation in
terms of risk stratiﬁcation, assembling and assessing the
perspectives, and evaluating the assessments of all the clini-
cians involved (ie, the surgeon’s, pulmonologist’s/oncologist’s,
cardiologist’s, and anesthesiologist’s). Surprisingly, all pre-
vious guidelines have failed to recognize the importance of
such a central ﬁgure.1-5 The authors hope that this approach
and proposed algorithm correctly interpret the actual processes
occurring in everyday clinical practice, bringing clarity to the
overall procedure. The pulmonologist’s perspective considers
the limits related to the residual pulmonary function and the
related risk of functional disability. The value of arterial
oxygen tension, clearly pivotal for evaluating risk in pulmonary
resection, is easy to assess during the entire perioperative
period. The cardiologist’s perspective is essential for adapting
the therapy. The assessment of functional cardiac reserve is
mandatory for all patients with a high risk of MACE. The
prophylactic use of beta-blockers, statins, and amiodarone
during the perioperative period needs to be considered. The
surgeon’s perspective describes the indications, levels of
complexity, and complications associated with the different
lung resection procedures and also must be respectful of the
informed patient’s wishes.
Adopting a multidisciplinary preoperative assessment
approach to lung resection will increase hospital efﬁciency and
save resources.9,10,28 By identifying HRSPs, the most suitable
measures to evaluate can be identiﬁed to optimize anesthesia
management, hemodynamics, and postoperative recovery in the
ICU.37-39 Patients undergoing bilobectomy, pneumonectomy, or
other major resections need to be treated in a protective
environment by specialized physicians and nurses, in the ICU.43
The proposed multidisciplinary approach is not without
limitations. Preoperative assessment of functional capacity uses
METS as its unit of measure, which indicates energy expenditure
as multiples of the baseline metabolic rate, assumed to be 3.5 mL
of oxygen per kg of body weight per minute.88 Some “asympto-
matic patients” with unknown AF or serious AV block or a prior
asymptomatic myocardial infarction and METS44, also may
require cardiologist consultation. CPET generally is considered to
be the “gold standard” for the assessment of exercise capacity;
however, patients with severe morbidity (including a history of
cardiac ischemic events) may not be able to undergo this or other
subjective tests of cardiorespiratory reserve, such as metabolic
equivalency tests.89,90CONCLUSIONS
The assessment of risk related to lung resection is a complex
process that takes into account the results of a multitude of
DELLA ROCCA ET AL536patient tests (including pulmonary and cardiac evaluation),
intervention type, age, and other risk factors. Many specialists
should be involved in risk stratiﬁcation at the preoperative
stage and in the perioperative management of the patient, as
widely described by the most recent quality models of
perioperative medicine. A team consisting of just pulmonolo-
gists/oncologists and thoracic surgeons, who play fundamental
roles in selecting the best cancer treatments, is not necessarily
well-equipped for the comprehensive management and risk
stratiﬁcation of the candidate for surgical treatment. Only a
multidisciplinary team that includes the aforementioned spe-
cialists and an anesthesiologist, who is involved in themanagement of the patient, is able to assess the overall risk
of the procedure, optimize the perioperative conditions and
plan the appropriate treatment regimens to minimize post-
operative complications and length of hospital stay. In this
way, joint decisions can be made for each patient, even when
the literature presents different opinions based on the various
individual perspectives. Of the various specialists involved, it is
the anesthesiologist, together with the surgeon, who observe
the patient throughout the duration of treatment, including the
preoperative, intraoperative, and postoperative periods; thus,
the anesthesiologist is best equipped to tailor and optimize the
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